21 April 2023 : Original article
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
Chih-Hsien Cheng1ABCDE*, Hao-Chien Hung1BC, Jin-Chiao Lee1BC, Yu-Chao Wang1CD, Tsung-Han Wu1CD, Chen-Fang Lee1ABC, Ting-Jung Wu1BC, Hong-Shiue Chou1BC, Kun-Ming Chan
1BC, Wei-Chen Lee1ABCD
DOI: 10.12659/AOT.938731
Ann Transplant 2023; 28:e938731
Table 1 Patient characteristics.
| Age (years), median (range) | 54 (35–67) |
| Sex, male/female, n | 15/2 |
| MELD, median (IQR) | 19 (9–27) |
| Indication for transplantation, n (%) | |
| Hepatic failure | 5 (29.4) |
| Complications of liver cirrhosis | 4 (23.5) |
| HCC | 8 (47) |
| Pre-transplant comorbidity, n (%) | |
| HTN | 4 (23.5) |
| DM | 3 (17.6) |
| Type of transplant, n (%) | |
| LDLT | 10 (58.8) |
| DDLT | 4 (23.5) |
| SLT | 3 (17.7) |
| HBeAg positive, n (%) | 4 (23.5) |
| Quantitative HBsAg (IU/ml), median (IQR) | 243 (43–153332) |
| HBV DNA (IU/ml), median (IQR) | 182 (20–68330000) |
| HCV coinfection, n (%) | 1 (5.9) |
| Duration of TDF treatment (days), median (range) | 1137 (579–1639) |
| HBsAg persistence, n (%) | 7 (41.1) |
| HBV recurrence, n (%) | 6 (35.3) |
| Therapy, naïve/with previous therapy/switch after recurrence, n | 6/5/6 |
| MELD – Model For End-Stage Liver Disease; HCC – hepatocellular carcinoma; HTN – hypertension; DM – diabetes mellitus; LDLT – living donor liver transplantation; DDLT – deceased donor liver transplantation; SLT – split liver transplantation; IQR – interquartile range; HBeAg – hepatitis B e antigen; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HCV – hepatitis C virus; HCC – hepatocellular carcinoma; TDF – tenofovir disoproxil fumarate. | |